Gliatilin

General characteristics. Structure:

Capsules 1 капс.
sincaline альфосцерат 400 mg
excipients: the purified water — 140 mg; glycerin — 50 mg  
structure of a cover of the capsule: gelatin — 152 mg; эзитол — 41 mg; сорбитанс — 33 mg; ethylparahydroxysodium benzoate — 0,8 mg; пропилпарагидроксибензоат sodium — 0,4 mg; titanium dioxide (E171) — 2,4 mg; gland (III) metahydroxide (E172) — 1,1 mg  
in a blister strip packaging of 14 pieces; in a box 1 packaging.

 

Solution for intravenous and intramuscular administration of 4 ml
sincaline альфосцерат 1000 mg
solvent: water for injections — q.s. to 4 ml  
in ampoules on 4 ml; in a box 3 ampoules.

Pharmacological properties:

Pharmacological action - neuroprotective.

Pharmacokinetics. Absorption at intake — 88%; easily gets through GEB, collects preferential in a brain (concentration in a brain reaches 45% of level in blood), lungs and a liver; 85% are excreted by lungs in the form of carbon dioxide, other quantity (15%) is removed by kidneys and through intestines.
Does not influence a reproductive cycle, does not possess teratogenic and mutagen action.

Pharmacodynamics. Improves transfer of nervous impulses in cholinergic neurons; positively influences plasticity of neyronalny membranes and function of receptors. Improves a cerebral blood stream, strengthens metabolic processes in a brain, activates structures of a reticular formation of a brain and recovers consciousness at traumatic damage of a brain.
Has preventive and corrective effect on such pathogenetic factors of an involutional psychoorganic syndrome as change of phospholipidic structure of membranes of neurons and decrease in cholinergic activity.
Pilot studies showed that Gliatilin stimulates dozozavisimy allocation of acetylcholine in physiological conditions of neurotransmission.
At hit in an organism it is split under the influence of enzymes on sincaline and glycerophosphate.
Gliatilin, on the one hand, being a donor of sincaline, increases synthesis of acetylcholine and positively influences neurotransmission, with another — glycerophosphate participates in phosphatidylsincaline synthesis (membrane phospholipid), as a result both makes positive impact on membrane elasticity and on function of receptors that improves synoptic transmission.
Thus, pharmakodinamichesky researches showed that Gliatilin affects synoptic, including cholinergic neurotransmission; plasticity of a neural membrane; function of receptors.

Indications to use:

The acute period of a craniocereberal injury with preferential trunk level of defeat (consciousness disturbance, coma, focal polusharny symptomatology, symptoms of defeat of a brainstem);
ischemic (acute and recovery period) and hemorrhagic stroke (recovery period);
degenerative or involutional psychoorganic syndromes and effects of cerebrovascular insufficiency, such as primary and secondary disturbances of mnestichesky functions which are characterized by memory disturbances, confusion of consciousness, a disorientation, decrease in motivation, initiative, ability to concentration of attention;
changes in the emotional and behavioural sphere: emotional lability, acrimony, decrease in interest, senile pseudo-melancholy;
multiinfarctive dementia.

Route of administration and doses:

Injections: in oil or in/in (kapelno).
Capsules: inside, to food.
The adult, at acute states: in oil — in a dose of 1000 mg/days (1 amp.) or in/in — 1000–3000 mg/days. At in introduction contents of 1 amp. (4 ml) part in 50 ml of normal saline solution, infusion speed — 60–80 drops a minute. Treatment duration — usually 10 days, but if necessary it is possible to continue treatment before emergence of positive dynamics and an opportunity to pass to intake of capsules.
At chronic cerebrovascular insufficiency, changes in the emotional and behavioural sphere and multiinfarctive dementia: inside — on 400 mg (1 капс.) 3 times a day.
Therapy duration — 3–6 months.

Side effects:

Nausea (as a result of dopaminergic activation), in this case it is necessary to lower a drug dose. Allergic reactions are possible.
As a rule, drug is well transferred even at prolonged use.

Contraindications:

hypersensitivity to drug components;
pregnancy;
breastfeeding.

Use at pregnancy and feeding by a breast

Contraindicated at pregnancy and a lactation.

Overdose:

Symptoms: nausea.
At emergence of this symptom it is recommended to lower a drug dose.

Storage conditions:

Period of validity 3 years. List B.: At a temperature not above 25 °C.

Issue conditions:

According to the recipe

Packaging:

In a blister strip packaging of 14 pieces; in a pack cardboard 1 packaging. In ampoules on 4 ml; in a blister strip packaging on 1 or 3 ampoules, in a pack cardboard 1 planimetric packaging.